Elucidating the Role of HSD3B1 Genotype in Prostate Cancer Outcomes

by Manisha Kashyap, PhD

Prostate cancer progression hinges on androgen receptor (AR) signaling, primarily fueled by testosterone and its potent metabolite, 5α-dihydrotestosterone (DHT). While androgen deprivation therapy (ADT) initially restrains tumor growth, resistance mechanisms, notably intratumoral androgen synthesis, propel castration-resistant prostate cancer (CRPC). A pivotal enzyme in this process, 3β-hydroxysteroid dehydrogenase-1 (3β-HSD1), encoded by the HSD3B1 gene, has garnered significant attention. This posting synthesizes findings from a ground-breaking journal article and a comprehensive commentary, elucidating the clinical significance of HSD3B1 genotype in prostate cancer.

Login Or Register To Read Full Story